Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Human Immunodeficiency Virus (HIV) Therapeutics Market by Type (NRTIs, NNRTIs, Entry and Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors, Coreceptor Antagonists), By Application (Hospitals, Clinics, Labs) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Human Immunodeficiency Virus (HIV) Therapeutics Market by Type (NRTIs, NNRTIs, Entry and Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors, Coreceptor Antagonists), By Application (Hospitals, Clinics, Labs) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 247315 4200 Pharma & Healthcare 377 196 Pages 4.5 (40)
                                          

Industry Growth Insights published a new data on “Human Immunodeficiency Virus (HIV) Therapeutics Market”. The research report is titled “Human Immunodeficiency Virus (HIV) Therapeutics Market research by Types (NRTIs, NNRTIs, Entry and Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors, Coreceptor Antagonists), By Applications (Hospitals, Clinics, Labs), By Players/Companies ViiV Healthcare, Mylan, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc., Cipla, Inc., Boehringer Ingelheim GmbH, Genentech, Inc.”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Human Immunodeficiency Virus (HIV) Therapeutics Market Research Report

By Type

NRTIs, NNRTIs, Entry and Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors, Coreceptor Antagonists

By Application

Hospitals, Clinics, Labs

By Companies

ViiV Healthcare, Mylan, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc., Cipla, Inc., Boehringer Ingelheim GmbH, Genentech, Inc.

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

196

Number of Tables & Figures

138

Customization Available

Yes, the report can be customized as per your need.


Global Human Immunodeficiency Virus (HIV) Therapeutics Industry Outlook


Global Human Immunodeficiency Virus (HIV) Therapeutics Market Report Segments:

The global Human Immunodeficiency Virus (HIV) Therapeutics market is segmented on the basis of:

Types

NRTIs, NNRTIs, Entry and Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors, Coreceptor Antagonists

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospitals, Clinics, Labs

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. ViiV Healthcare
  2. Mylan
  3. AbbVie
  4. Merck & Co., Inc.
  5. Bristol-Myers Squibb Company
  6. Boehringer Ingelheim GmbH
  7. Genentech, Inc.
  8. Cipla, Inc.
  9. Boehringer Ingelheim GmbH
  10. Genentech, Inc.

Global Human Immunodeficiency Virus (HIV) Therapeutics Market Overview


Highlights of The Human Immunodeficiency Virus (HIV) Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. NRTIs
    2. NNRTIs
    3. Entry and Fusion Inhibitors
    4. Protease Inhibitors
    5. Integrase Inhibitors
    6. Coreceptor Antagonists
  1. By Application:

    1. Hospitals
    2. Clinics
    3. Labs
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Human Immunodeficiency Virus (HIV) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Human Immunodeficiency Virus (HIV) Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


HIV therapies are medications used to treat HIV infection. These medications help the body fight off the virus and keep it from replicating. There are several different types of HIV therapies, each with its own specific benefits and drawbacks. Some common HIV therapies include antiretroviral drugs (ARVs), which work by blocking the virus' ability to replicate; protease inhibitors, which prevent the virus from breaking down proteins in cells; and nucleoside analogues, which interfere with how viral DNA is copied into new viruses.

Some of the major companies in the human immunodeficiency virus (hiv) therapeutics market are ViiV Healthcare, Mylan, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc., Cipla, Inc., Boehringer Ingelheim GmbH, Genentech, Inc..

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Immunodeficiency Virus (HIV) Therapeutics Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Human Immunodeficiency Virus (HIV) Therapeutics Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Human Immunodeficiency Virus (HIV) Therapeutics Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size & Forecast, 2018-2028       4.5.1 Human Immunodeficiency Virus (HIV) Therapeutics Market Size and Y-o-Y Growth       4.5.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Absolute $ Opportunity

Chapter 5 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Type
      5.2.1 NRTIs
      5.2.2 NNRTIs
      5.2.3 Entry and Fusion Inhibitors
      5.2.4 Protease Inhibitors
      5.2.5 Integrase Inhibitors
      5.2.6 Coreceptor Antagonists
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Applications
      6.2.1 Hospitals
      6.2.2 Clinics
      6.2.3 Labs
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Human Immunodeficiency Virus (HIV) Therapeutics Analysis and Forecast
   9.1 Introduction
   9.2 North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Type
      9.6.1 NRTIs
      9.6.2 NNRTIs
      9.6.3 Entry and Fusion Inhibitors
      9.6.4 Protease Inhibitors
      9.6.5 Integrase Inhibitors
      9.6.6 Coreceptor Antagonists
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Applications
      9.10.1 Hospitals
      9.10.2 Clinics
      9.10.3 Labs
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Human Immunodeficiency Virus (HIV) Therapeutics Analysis and Forecast
   10.1 Introduction
   10.2 Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Type
      10.6.1 NRTIs
      10.6.2 NNRTIs
      10.6.3 Entry and Fusion Inhibitors
      10.6.4 Protease Inhibitors
      10.6.5 Integrase Inhibitors
      10.6.6 Coreceptor Antagonists
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Applications
      10.10.1 Hospitals
      10.10.2 Clinics
      10.10.3 Labs
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Human Immunodeficiency Virus (HIV) Therapeutics Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Type
      11.6.1 NRTIs
      11.6.2 NNRTIs
      11.6.3 Entry and Fusion Inhibitors
      11.6.4 Protease Inhibitors
      11.6.5 Integrase Inhibitors
      11.6.6 Coreceptor Antagonists
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Applications
      11.10.1 Hospitals
      11.10.2 Clinics
      11.10.3 Labs
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Type
      12.6.1 NRTIs
      12.6.2 NNRTIs
      12.6.3 Entry and Fusion Inhibitors
      12.6.4 Protease Inhibitors
      12.6.5 Integrase Inhibitors
      12.6.6 Coreceptor Antagonists
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Applications
      12.10.1 Hospitals
      12.10.2 Clinics
      12.10.3 Labs
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Human Immunodeficiency Virus (HIV) Therapeutics Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Type
      13.6.1 NRTIs
      13.6.2 NNRTIs
      13.6.3 Entry and Fusion Inhibitors
      13.6.4 Protease Inhibitors
      13.6.5 Integrase Inhibitors
      13.6.6 Coreceptor Antagonists
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Applications
      13.10.1 Hospitals
      13.10.2 Clinics
      13.10.3 Labs
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Human Immunodeficiency Virus (HIV) Therapeutics Market: Competitive Dashboard
   14.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 ViiV Healthcare
      14.3.2 Mylan
      14.3.3 AbbVie
      14.3.4 Merck & Co., Inc.
      14.3.5 Bristol-Myers Squibb Company
      14.3.6 Boehringer Ingelheim GmbH
      14.3.7 Genentech, Inc.
      14.3.8 Cipla, Inc.
      14.3.9 Boehringer Ingelheim GmbH
      14.3.10 Genentech, Inc.

Our Trusted Clients

Contact Us